• K-REN

  Led · Equity · May 2026

  K Ren designs and manufactures submerged textile hull covers intended to limit biofouling by preventing photosynthesis and the growth of microorganisms, avoiding the diffusion of biocides. Founded in 2020 and based in Mauguio (Hérault), the company produces its covers in France from domestically sourced materials. K Ren targets boats that remain long at berth and those sensitive to hull performance, and it highlights fuel- and performance-related benefits from cleaner hulls. The company plans to use the €1.2M raised to industrialise production and scale commercial deployment. Its fundraising included institutional and angel investors as well as a participative campaign that collected over €120,000 from existing users, including noted sailors who have tested the product.

• Lisaqua

  Participated · Debt Financing · Apr 2026

  Founded in 2018 by Charlotte Schoelinck and Gabriel Boneu, Lisaqua operates a pilot on-land shrimp farm in Saint-Herblain that has been active since 2022. The company uses systems of natural filtration to raise shrimp without antibiotics or sulfites while reducing resource consumption and avoiding impacts on tropical mangroves and coastal ecosystems. Lisaqua completed an equity raise of more than €9M in H2 2025 and has now secured €14.5M in bank financing to scale. The funding package includes a €10.5M Blue Loan and a €4M Prêt Nouvelle Industrie from Bpifrance. Proceeds will finance construction of an industrial farm in Monthyon, Seine-et-Marne, slated to begin operations at the end of 2026. The new site is expected to produce about 100 tonnes of shrimp per year.

• DiappyMed

  Participated · Equity · Mar 2026

  DiappyMed builds a digital therapy designed to personalize insulin dose calculations for people with type 1 or type 2 diabetes treated with a basal/bolus regimen. The company presents its solution as the first French therapy numérique dedicated to individualized insulin dosing and says it works with professionals de santé and patients. DiappyMed announced a strategic partnership with Sanofi to enable broad deployment of the therapy across France. The company aims to secure reimbursement from Assurance Maladie by 2026 and frames the recent financing and partnership as steps toward that objective. In support of its rollout, DiappyMed raised €5 million in an amorçage round led by Ventech and AFI Ventures with participation from SOFILARO/CALEN and IRDI Capital Investissement, and cited additional institutional partners and supporters. No revenue, user metrics, founding year, or valuation were disclosed in the available articles.

• Anodine

  Participated · Equity · Jan 2026

  Anodine is a Gières-based cleantech startup that has developed an industrial process to upcycle and recharge electrolyzer electrodes, reducing the need for rare metals by half. The technology stems from ten years of research at Université Grenoble Alpes and the CNRS and is designed to lessen European dependence on Chinese-supplied electrodes while curbing global waste. With a seven-person team, the company plans to install a pilot line capable of producing 200,000 electrodes annually and to expand its commercial organization. Management’s longer-term goal is to become the leading European provider of sustainable electrodes for the hydrogen industry. In January 2026 Anodine closed a €2.5 million first funding round to finance the pilot facility and accelerate go-to-market efforts. The startup, founded in 2024, projects €2.5 million in revenue by 2027 as it moves from pilot to scaled production.

• Kondree

  Participated · Equity · Jan 2026

  Founded in 2021, Kondree focuses on mitigating oxidative stress to improve the quality of life of patients with facioscapulohumeral muscular dystrophy (FSHD), a severely disabling form of myopathy. The company’s long-term solution will combine a digital medical device (DMN) with complementary antioxidant medications. With a current team of four employees and support from the SATT AxLR tech-transfer organization, Kondree is first building practitioner decision-support software. The freshly secured capital will fund the completion of this initial software and prepare for a planned European launch in 2026. Concurrently, Kondree will initiate the clinical protocol and CE-mark process for its future DMN. A larger financing round is already envisioned for 2027 to scale deployment across Europe and globally. The company is positioning itself at the intersection of digital health and therapeutics, targeting a niche yet high-need rare disease market.

No current team members are available.